

**In the Claims:**

Please amend claims 1-13 in the following manner:

1. [AMENDED] A conjugate metal complexing agent having attached thereto at least one substituent of formula

(metal complexing agent)–((Y)<sub>m</sub>–A–NHR)<sub>k</sub>,

where:

k is a natural number;

Y is the same or different at different locations within the molecule and is independently chosen from: an A group, a C<sub>4-8</sub> cycloheteroalkylene group, a C<sub>4-8</sub> cycloalkylene group, a C<sub>5-12</sub> arylene group, a C<sub>3-12</sub> heteroarylene group, or a polyalkyleneglycol, polyactic acid or polyglycolic acid moiety,

m is an integer of value 0-20,

A is a 3-10 atom chain of units selected from –CR<sub>2</sub>–, –CR=CR–, –C≡C–, –NRCO–, –CONR–, –SO<sub>2</sub>NR–, –NRSO<sub>2</sub>–, or –CR<sub>2</sub>ZCR<sub>2</sub>– where Z is –CH<sub>2</sub>–, O, S, Se or –NR–,

R is the same or different at different locations within the molecule and is independently chosen from H, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkenyl, C<sub>1-4</sub> alkynyl, C<sub>1-4</sub> alkoxyalkyl or C<sub>1-4</sub> hydroxyalkyl,

with the proviso that the metal complexing agent does not also have attached thereto a hypoxia localising moiety.

2. [AMENDED] The conjugate metal complexing agent of claim 1, wherein A is

–NHCO(CH<sub>2</sub>)<sub>2</sub>Z(CH<sub>2</sub>)<sub>2</sub>–, or  
–SO<sub>2</sub>NH(CH<sub>2</sub>)<sub>2</sub>Z(CH<sub>2</sub>)<sub>2</sub>–, or  
–(CH<sub>2</sub>)<sub>2</sub>Z(CH<sub>2</sub>)<sub>2</sub>–.

3. [AMENDED] The conjugate metal complexing agent of claim 1 or claim 2, wherein Z is CH<sub>2</sub>.

4. [AMENDED] The conjugate metal complexing agent of any one of claims 1 to 3 of claim 1, wherein the at least one substituent has the formula



5. [AMENDED] The conjugate metal complexing agent of any one of claims 1 to 4 of claim 1, wherein the substituent has the formula



where b is an integer of value 0 to 19 and Ar is an arylene or heteroarylene group.

6. [AMENDED] The conjugate metal complexing agent of any one of claims 1 to 5 of claim 1, wherein the metal complexing agent is a metal chelating agent.

7. [AMENDED] The cojugate metal complexing agent of claim 6, wherein the metal chelating agent is a diaminedioxime.

8. [AMENDED] A metal complex of one or more radiometal or paramagnetic metal ions with the conjugate metal complexing agent of claim 1 any one of claims 1 to 7.

9. The metal complex of claim 8, wherein the radiometal is <sup>99m</sup>Tc, <sup>111</sup>In or <sup>67</sup>Ga.

10. [AMENDED] The metal complex of claim 8 or claim 9 for use in the diagnosis or therapy of thrombosis, embolism, atherosclerosis, inflammation or cancer.
11. [AMENDED] A kit for the preparation of the metal complex of claim 8 ~~any one of claims 8 to 10~~.
12. [AMENDED] A vessel containing a unit dose for human administration of the metal complex of claim 8 ~~any one of claims 8 to 10~~.
13. [AMENDED] A method of preparing a composition for use in the diagnosis or therapy of thrombosis, [,] atherosclerosis, inflammation or cancer, which method comprises bringing the metal complex of claim 8 ~~any one of claims 8 to 10~~ into a form suitable for human administration.